Evaluation of albendazole efficiency and complications in patients with pulmonary hydatid cyst

Abstract

Objectives: This study investigated the efficacy and complications of albendazole use after surgery in patients with pulmonary hydatid cysts.

Methods: One hundred fifty-three consecutive patients who met the study criteria out of 215 patients who received prophylaxis with albendazole after surgery for isolated pulmonary hydatid cysts in our clinic between January 2011 and December 2020 were analysed retrospectively.

Results: Eighty-six out of 153 (56.2%) of cases were male and 67 (43.8%) were female. The average age was 24.6 ± 17.4 (between 3 and 71 years), 76 of them (49.7%) were 18 years old and younger, while 77 (50.3%) were adults. All cases were approached transthoracically and a total of 170 operations were performed on the 153 cases. Fever, weakness and dizziness were reported in only one patient who was given albendazole treatment. A partial increase in liver enzymes was observed in 16 cases (10.5%) after albendazole treatment. Mild leukopoenia and neutropenia were observed in only one of the cases. In 1 case, a second operation was performed 30 months later due to recurrence. Albendazole treatment was not required to be discontinued in any of the cases. Mortality was not observed in any of the cases. Factors such as mean age, cyst size and hospitalization period did not have a statistically significant effect on any changes in liver enzymes tests following albendazole therapy (P > 0.05).

Conclusions: Albendazole treatment can safely be used for postoperative prophylaxis in patients with pulmonary hydatid cysts in a controlled manner without causing serious complications.

Subj collection: 152.

Keywords: Albendazole; Complication; Hydatid cyst; Lung; Reliability.

Figure 1:

Posteroanterior chest X-ray (A) and axial thorax computed tomography scan (B) of a 22-year-old male patient who had a giant hydatid cyst of ∼44 mm × 123 mm × 185 mm in the right lower lobe and recurred later.